These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 29351242)

  • 1. "Vessels in the Storm": Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer.
    Angelucci A; Delle Monache S; Cortellini A; Di Padova M; Ficorella C
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29351242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Angiogenics: Their Value in Colorectal Cancer Therapy.
    Seeber A; Gunsilius E; Gastl G; Pircher A
    Oncol Res Treat; 2018; 41(4):188-193. PubMed ID: 29562227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival.
    Paiva TF; de Jesus VH; Marques RA; da Costa AA; de Macedo MP; Peresi PM; Damascena A; Rossi BM; Begnami MD; de Lima VC
    BMC Cancer; 2015 Sep; 15():643. PubMed ID: 26394830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of tumor angiogenesis as a therapeutic target in colorectal cancer.
    Battaglin F; Puccini A; Intini R; Schirripa M; Ferro A; Bergamo F; Lonardi S; Zagonel V; Lenz HJ; Loupakis F
    Expert Rev Anticancer Ther; 2018 Mar; 18(3):251-266. PubMed ID: 29338550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
    Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
    Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
    Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
    Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive tissue biomarkers for bevacizumab-containing therapy in metastatic colorectal cancer: an update.
    Marien KM; Croons V; Martinet W; De Loof H; Ung C; Waelput W; Scherer SJ; Kockx MM; De Meyer GR
    Expert Rev Mol Diagn; 2015 Mar; 15(3):399-414. PubMed ID: 25585649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer.
    Fakih M
    Expert Rev Anticancer Ther; 2013 Apr; 13(4):427-38. PubMed ID: 23432698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
    Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J
    Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis and its role in colorectal tumor and metastasis formation.
    Ellis LM
    Semin Oncol; 2004 Dec; 31(6 Suppl 17):3-9. PubMed ID: 15696024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
    Leite de Oliveira R; Hamm A; Mazzone M
    Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
    Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
    Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
    García-Alfonso P; Grande E; Polo E; Afonso R; Reina JJ; Jorge M; Campos JM; Martínez V; Angeles C; Montagut C
    Angiogenesis; 2014 Oct; 17(4):805-21. PubMed ID: 24793846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer.
    Giampieri R; Scartozzi M; Del Prete M; Fulli A; Faloppi L; Bianconi M; Maccaroni E; Cascinu S
    Cancer Treat Rev; 2014 Sep; 40(8):934-41. PubMed ID: 24997679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenesis in cancer - general pathways and their therapeutic implications.
    Dimova I; Popivanov G; Djonov V
    J BUON; 2014; 19(1):15-21. PubMed ID: 24659637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disrupting Tumor Angiogenesis and "the Hunger Games" for Breast Cancer.
    Zhou Z; Yao H; Hu H
    Adv Exp Med Biol; 2017; 1026():171-195. PubMed ID: 29282684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive review of targeted therapy for colorectal cancer.
    Xie YH; Chen YX; Fang JY
    Signal Transduct Target Ther; 2020 Mar; 5(1):22. PubMed ID: 32296018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging VEGF-receptor inhibitors for colorectal cancer.
    Martinelli E; Troiani T; Morgillo F; Orditura M; De Vita F; Belli G; Ciardiello F
    Expert Opin Emerg Drugs; 2013 Mar; 18(1):25-37. PubMed ID: 23216053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer.
    Sanz-Garcia E; Saurí T; Tabernero J; Macarulla T
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):995-1004. PubMed ID: 25988772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.